

# Resource Summary Report

Generated by [RRID](#) on Sep 5, 2026

## PE anti-human CD8

RRID:AB\_2616623

Type: Antibody

### Proper Citation

BioLegend Cat# 980902, RRID:AB\_2616623

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2616623](http://antibodyregistry.org/AB_2616623)

**Proper Citation:** BioLegend Cat# 980902, RRID:AB\_2616623

**Target Antigen:** CD8

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Applications: FC

**Antibody Name:** PE anti-human CD8

**Description:** This monoclonal targets CD8

**Target Organism:** human

**Clone ID:** Clone SK1

**Antibody ID:** AB\_2616623

**Vendor:** BioLegend

**Catalog Number:** 980902

**Record Creation Time:** 20231110T034921+0000

**Record Last Update:** 20260829T071823+0000

### Ratings and Alerts

No rating or validation information has been found for PE anti-human CD8.

No alerts have been found for PE anti-human CD8.

## Data and Source Information

**Source:** [Antibody Registry](#)

## Usage and Citation Metrics

We found 3 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Jones RD, et al. (2026) Tunable differentiation of human CD4+ and CD8+ T cells from pluripotent stem cells. *Cell stem cell*, 33(1), 73.

Li YR, et al. (2026) Spatiotemporal profiling reveals distinct dynamics and checkpoint regulations of CAR-T and CAR-NKT cells against solid tumors. *Signal transduction and targeted therapy*, 11(1).

Kaczanowska S, et al. (2024) Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. *Cancer cell*, 42(1), 35.